Reig Jofré joins generics manufacturer Mylan to enter US market
This Catalan pharmaceutical group expects to start selling its products in this market in late 2014. They currently export 55% of their drugs.
By Biocat
The Reig Jofré Group has signed an alliance agreement with Mylan Pharmaceuticals, the third generic-drugs manufacturer in the world, to register and distribute an antibiotic for hospital use on the US market. Mylan is based in Virginia (USA) and has had a subsidiary in Barcelona since 2007.
This Catalan group has been run by the Reig family since 1929 and specializes in injectable drugs, both lyophilized and penicillin-based antibiotics. Their activity currently focuses on four divisions: industrial services, pharma, R&D and biotechnology services. The company is reinforcing its expansion through internationalization, which led to turnover of €118 millions in 2012, 55% of which was from exports.
Thanks to their purchase of Bioglan AB in 2009, the group has strategically penetrated the Medicon Valley cluster in southern Sweden and has developed a spray to prevent allergic reactions, which they expect to launch globally in the middle term. Additionally, together with biotechnology firm Oryzon Genomics they have launched a non-invasive test to detect endometrial cancer (GynEC®-DX).
Other markets of interest in which they are currently negotiating include the Czech Republic, Hungary, Norway, Korea, Japan, Pakistan, Egypt and Algeria.
Reig Jofré is one of the companies sponsoring the BIO-Europe Spring 2013 partnering congress, which will be held in Barcelona from 11 to 13 March and bring together leaders of the biotechnology and pharmaceutical industry from around the world, under the umbrella of the Barcelona City Council and Biocat, among other bodies.